Evidence map›Paper›PMID 40553169›Full record

ReviewAnnals of hematology2025

Inborn errors of immunity presenting with lymphoproliferation: lessons from a case series.

Giorgio Costagliola, Emanuela De Marco, Filippo Consonni, Valeria Rocchi, Annalisa Legitimo, Mariacristina Menconi, Eleonora Gambineri, Gabriella Casazza, Rita Consolini

Abstract readReview
In one paragraph

Review in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Quality and Safety Intervention: Improving Care of Patients Undergoing B Cell-Targeted Therapies.The journal of allergy and clinical immunology. In practice · 2026
    Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giorgio CostagliolaSection of Pediatric Hematology and Oncology, Azienda Ospedaliero- Universitaria Pisana, Pisa, Italy.ORCID http://orcid.org/0000-0002-4160-3727
Emanuela De MarcoSection of Pediatric Hematology and Oncology, Azienda Ospedaliero- Universitaria Pisana, Pisa, Italy.
Filippo ConsonniDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy. filippo.consonni@unifi.it.ORCID http://orcid.org/0000-0002-6879-8982
Valeria RocchiClinical Immunology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy.
Annalisa LegitimoSection of Clinical and Laboratory Immunology, Pediatric Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Mariacristina MenconiSection of Pediatric Hematology and Oncology, Azienda Ospedaliero- Universitaria Pisana, Pisa, Italy.
Eleonora GambineriDivision of Pediatric Oncology/Hematology, Meyer Children's Hospital IRCCS, Florence, Italy.ORCID http://orcid.org/0000-0002-4676-6541
Gabriella CasazzaSection of Pediatric Hematology and Oncology, Azienda Ospedaliero- Universitaria Pisana, Pisa, Italy.
Rita ConsoliniSection of Clinical and Laboratory Immunology, Pediatric Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymphoproliferation can represent the first or leading disease sign in different inborn errors of immunity (IEI), which include autoimmune lymphoproliferative syndrome (ALPS), common variable immunodeficiency (CVID), combined immunodeficiencies, activated phosphoinositide 3-kinase δ syndrome (APDS), Epstein-Barr (EBV)-related disorders, and others. The genetic and molecular background and the clinical implications of IEI presenting with lymphoproliferation are partly unexplored. Therefore, the diagnosis and clinical management of this category of patients is particularly challenging. As treatments targeting the specific genetic defect are available for some of the IEIs associated with lymphoproliferation, identifying the molecular diagnosis is of great clinical relevance and could significantly improve the patient's long-term outcome. To this purpose, a first-level immunological assessment is strongly recommended in patients with persistent or recurrent unexplained lymphoproliferation, and specific second-level analysis can orient towards the correct clinical suspicion. The mechanisms responsible for polyclonal, benign lymphoproliferation in IEI also cause an increased susceptibility to clonal, malignant lymphoproliferation. Therefore, a careful follow-up is recommended in all the patients with IEI and polyclonal lymphoproliferation, to promptly identify the development of clonality. Moreover, as malignant lymphoproliferation can be the first disease sign of some IEI, there is increasing interest in the possibility of recognizing IEIs in patients presenting with lymphoid malignancies. This work, by describing some relevant case studies, reviews the role of lymphoproliferative features in three of the most paradigmatic conditions, particularly ALPS, CVID, and APDS, and provides an updated discussion on the diagnosis, treatment, and follow-up of patients with IEI and lymphoproliferative features.

Indexed as

Lymphoproliferative DisordersAutoimmune Lymphoproliferative SyndromeCommon Variable ImmunodeficiencyHumansPrimary Immunodeficiency DiseasesActivated phosphoinositide 3-kinase δ syndromeAutoimmune lymphoproliferative syndromeCommon variable immunodeficiencyHodgkin lymphomaLymphadenopathyPediatricsSplenomegaly

Identifiers

PMID40553169
PMCPMC12283836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.